Table 5 The adjusted effect models

Const

47.519***

43.481***

34.610***

47.339***

47.447***

(21.051–73.987)

(20.399–66.563)

(10.496–58.724)

(20.998–73.681)

(20.861–74.033)

Measure

 EORTC

3141

65.15

0.184

-1.610

4.285

0.040

-0.921

(-26.512–26.881)

(-26.576–23.356)

(-19.078–27.648)

(-26.512–26.591)

(-27.934–26.092)

 FACT

584

12.11

-2.111

-6.564

1.557

-2.293

-3.578

(-31.500–27.279)

(-32.908–19.779)

(-23.929–27.042)

(-31.891–27.305)

(-33.276–26.119)

 SF36

466

9.67

27.583

16.859

30.574*

26.836

24.989

(-8.753–63.918)

(-14.484–48.203)

(-0.489–61.636)

(-9.600–63.271)

(-12.163–62.141)

 QLI

59

1.22

-4.078

-2.128

-2.855

-4.236

-5.215

(-34.823–26.667)

(-33.027–28.772)

(-30.749–25.040)

(-34.783–26.311)

(-35.977–25.548)

 FLIC

55

1.14

31.146

23.858

41.435*

30.254

29.797

(-20.313–82.605)

(-26.729–74.445)

(-6.886–89.757)

(-20.421–80.928)

(-20.825–80.419)

 VAS

23

0.48

-43.518**

-46.011**

-41.824**

-43.561**

-43.851**

(-79.783 - -7.252)

(-83.782 - -8.239)

(-76.787 - -6.862)

(-79.765 - -7.358)

(-80.270 - -7.432)

 Other

456

9.46

-24.614*

-29.579**

-21.882*

-25.147*

-25.409*

(-50.459–1.231)

(-52.579 - -6.580)

(-44.499–0.735)

(-50.800–0.506)

(-51.439–0.620)

Types of cancer

 Breast cancer

787

16.32

6.310

(-7.831–20.451)

 Head and Neck cancer

688

14.27

-0.615

(-13.797–12.567)

 Research evaluating more than one type of cancer

540

11.20

5.158

(-6.084–16.400)

 Prostate cancer

406

8.42

26.599***

(12.554–40.643)

 Esophageal or gastroesophageal junction cancer

230

4.77

16.410***

(5.891–26.928)

 Ovarian cancer

135

2.80

10.208

(-18.694–39.109)

 Gastric cancer

122

2.53

27.848*

(-3.809–59.505)

 Gastrointestinal cancer

119

2.47

-4.927

(-13.258–3.404)

 Endometrial Cancer

114

2.36

-5.708

(-18.357–6.942)

 Nasopharyngeal carcinoma

90

1.87

4.845

(-5.746–15.436)

 Esophageal cancer

84

1.74

16.134

(-18.555–50.822)

 Cervical cancer

80

1.66

-18.021***

(-28.612 - -7.430)

 Leukemia

77

1.60

26.837*

(-3.725–57.398)

 Gynecological Cancer

73

1.51

14.543

(-8.913–37.998)

 Colorectal cancer

71

1.47

20.009***

(9.418–30.600)

 Pancreatic cancer

60

1.24

-0.251

(-10.842–10.340)

 laryngeal cancer

58

1.20

5.969

(-10.065–22.003)

 Sarcoma

57

1.18

-6.667

(-17.258–3.924)

 Malignant Melanoma

54

1.12

-17.089

(-49.960–15.782)

 Rectal cancer

53

1.10

-8.052

(-18.643–2.539)

 Hodgkin Lymphoma

42

0.87

29.844***

(19.253–40.435)

 Eye cancer

30

0.62

6.765

(-3.826–17.356)

 Rectal cell cancer

30

0.62

-0.208

(-10.799–10.383)

 Carcinoma

28

0.58

-4.324

(-14.915–6.267)

 Brain cancer

18

0.37

41.822***

(33.388–50.257)

 Bone cancer

6

0.12

6.672

(-13.840–27.184)

 Acute myeloid leukemia

2

0.04

95.083***

(81.332–108.835)

 Kidney cancer

2

0.04

-43.241***

(-66.323 - -20.159)

Types of interventions

 Chemotherapy + Radiotherapy

623

12.92

0.703

(-13.855–15.260)

 Psychological support program

611

12.67

4.729

(-8.024–17.482)

 Radiotherapy

368

7.63

30.588***

(17.327–43.850)

 Palliative care

336

6.97

18.355**

(3.308–33.403)

 Chemotherapy + Radiotherapy + Surgery

255

5.29

-0.395

(-11.495–10.705)

 Radiotherapy + surgery

250

5.19

-6.789

(-26.329–12.750)

 Physical exercise

236

4.90

13.728**

(0.180–27.275)

 Combine curative and palliative care

218

4.52

23.787**

(2.813–44.762)

 Chemotherapy + surgery

182

3.78

4.846

(-4.855–14.548)

 Psychological group therapy

165

3.42

-3.831

(-12.328–4.666)

 Short term psycho-educational

110

2.28

-0.648

(-9.118–7.823)

 Stem Cell Transplantation

80

1.66

4.324

(-15.740–24.388)

 Complementary Alternative therapy

66

1.37

5.050

(-5.189–15.290)

 Best supportive care + chemotherapy

60

1.24

59.782***

(48.743–70.820)

 Screening

51

1.06

31.006***

(18.284–43.729)

 Anti-hormone Therapy

48

1.00

-2.414

(-17.791–12.962)

Country type

 Upper middle-income country

484

10.04

3.645

(-9.238–16.528)

Study design

 Randomized control trials

1410

29.25

2.321

(-7.952–12.593)

 Cohort study

687

14.25

4.912

(-4.602–14.426)

 Case-control study

256

5.31

9.143

(-19.333–37.619)